Liminatus PharmaLIMN -6.99%13 Net Debt Paydown Yield % is 239.18% as of Jul. 11, 2026, which is 276% above its 10-year median of 63.62. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,159 Biotechnology companies, Liminatus Pharma ranks better than 99.4% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Liminatus Pharma's Net Debt Paydown Yield % was 239.18%.
Liminatus Pharma (NAS:LIMN) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Liminatus Pharma Net Debt Paydown Yield % Related Terms
Liminatus Pharma Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Liminatus Pharma's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIMN vs GNPX, PCSA, ELAB: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Liminatus Pharma's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liminatus Pharma Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Liminatus Pharma's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 239.18% mean?
Liminatus Pharma (LIMN) has a Net Debt Paydown Yield % of 239.18% as of Jul. 11, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Liminatus Pharma and its competitors. This is 276% above median its historical median of 63.62. Over the past decade, Liminatus Pharma's Net Debt Paydown Yield % has ranged from 1.06 to 239.18. According to the industry distribution chart, Liminatus Pharma ranks #7 out of 1159 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Liminatus Pharma's Net Debt Paydown Yield % too high?
Liminatus Pharma's current Net Debt Paydown Yield % of 239.18% is 276% above median its 10-year median of 63.62. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 239.18. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Liminatus Pharma's value of 239.18% is 797166.7% above this industry median. Based on the distribution chart, Liminatus Pharma ranks #7 out of 1159 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Net Debt Paydown Yield % compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #7 out of 1159 companies for Net Debt Paydown Yield %. This places Liminatus Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Liminatus Pharma's value of 239.18% is 797166.7% above this benchmark. Historically, Liminatus Pharma's own Net Debt Paydown Yield % has ranged from 1.06 to 239.18 over the past decade. While the company's 10-year median is 63.62 vs. the industry median of 0.03, Liminatus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liminatus Pharma's current Net Debt Paydown Yield % of 239.18% is 797166.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Liminatus Pharma and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current Net Debt Paydown Yield % is 239.18%, which is 276% above median its own 10-year median of 63.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Net Debt Paydown Yield % of 239.18%. The current Net Debt Paydown Yield % is 239.18%, which is 276% above median its 10-year median of 63.62 and 797166.7% above the Biotechnology industry median of 0.03. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Net Debt Paydown Yield % is 239.18% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score
Get the complete analysis for LIMN
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIMN has been successfully added to your 
